NVSEF News and Press, Novartis Ag Basel Akt From 12/14/20

Tweedy Browne’s 13F portfolio value increased from $2.51B to $2.58B this quarter. The largest five individual stock positions are Berkshire Hathaway, Alphabet, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio. Tweedy Browne increas...

4D Molecular Therapeutics has filed proposed terms for its $100 million U.S. IPO. The firm is advancing genetic treatment programs for eye, cardio and pulmonary diseases. FDMT has produced promising preclinical study results and enjoys the financial support and collaboration effor...

Silverback Therapeutics has filed proposed terms for its $125 million IPO. The firm is advancing programs to treat various highly prevalent forms of cancer. SBTX has produced initially intriguing results but investors will likely need to wait until 2022 to see a meaningful catalys...

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy. The combination of high clinical f...

Kinnate Biopharma aims to raise $170 million in an IPO. The firm is developing kinase inhibitor-based treatment candidates for various cancers. KNTE has produced promising results in preclinical studies, but is still extremely high risk; the IPO may be more suited to long-term hol...

Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...

Novartis' shares are inexpensive and trade at a discount to its historic valuation range. Shares offer a solid dividend yield of 3.5% at current prices. Shareholders can expect solid total returns, and risks seem to be rather low with this stock. For further details see: ...

Olema Pharmaceuticals intends to raise $170 million in a U.S. IPO of its common stock. The firm is developing treatments for women's cancers, most particularly various breast cancers. It has a collaboration with major pharma firm Novartis and I value its focus on breast cancer tre...

Silverback Therapeutics has filed to raise $100 million in an IPO, although the final figure may differ. The firm is developing treatments for various cancers and Hepatitis B. SBTX may have had positive response rates in early trials for its lead candidate. For further detai...

Fisher’s 13F portfolio value increased from $102.5B to $117.8B in Q3 2020. They increased NextEra Energy, UnitedHealth, 3M Company, and Thermo Fisher Scientific while decreasing Starbucks, Total SA, and Royal Dutch Shell during the quarter. Fisher has a number of small posi...